Feasibility Study of BMAC Enhanced CABG
Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- The Methodist Hospital
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- University of Utah
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age> 18 years and ability to understand the planned treatment.
- Patients with ischemic congestive heart failure requiring by pass surgery
- Congestive heart failure with ejection fraction ≤ 40%.
- Serum bilirubin, SGOT and SGPT ≤2.5 time the upper level of normal.
- Serum creatinine < 3.0 or no dialysis.
- NYHA performance status ≥ 3.
- Negative pregnancy test (in women with childbearing potential).
- Subject has read and signed the IRB approved Informed Consent form
- Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery
Exclusion Criteria:
- Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
- History of Prior Radiation Exposure for oncological treatment.
- History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.
- History of abnormal Bleeding or Clotting.
- History of Liver Cirrhosis.
- Acute Myocardial Infarction < 4 weeks from treatment date.
- Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to be cancer free.
- Active clinical infection being treated by antibiotics within one week of enrollment
- Terminal renal failure with existing dependence on dialysis
- Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
- Unable to have 250cc bone marrow harvested.
- Medical risk that precludes anesthesia or ASA Class 5
- History of ventricular arrhythmia if AICD is not present.
- History of ventricular aneurysm.
- Concurrent surgery such as CABG with valve surgery.
- Minimally Invasive bypass surgery
- Life expectancy <6 months due to concomitant illnesses
- Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day)
- Patients undergoing urgent by pass surgical procedure
- Patients with HGB A1C > 8.5%
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Control
CABG only
|
Control subjects will undergo CABG surgery without BMAC injection
|
|
Eksperimentel: BMAC enhanced CABG
Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
|
Injection of BMAC into ischemic myocardium during CABG
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Cardiac Status (Classification)
Tidsramme: Through 12 months post treatment
|
A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation
|
Through 12 months post treatment
|
|
Safety
Tidsramme: through 1 Year post tx
|
as measured by frequency and severity of adverse events
|
through 1 Year post tx
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Harvest 2009-1
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .